Abstract
The coronavirus illness 2019 (COVID-19) has spread to over 200 countries and infected over 70 million individuals since December 2019. The precise nature of the SARS-CoV-2 infection is yet unknown. In this study, we look at whether a C-reactive protein biomarker can predict clinical outcome or is linked to the severity of COVID-19 illness. Potential research published from the COVID-19 pandemic to May 2022 was found using the databases MEDLINE, Hinari, Google Scholar, and Google search. To extract relevant facts from each original report, a format established in a Microsoft Excel spreadsheet was employed. The retrieved data were transferred to STATA/MP version 16.0 software for further analysis. Keywords such as "COVID-19," "SARS-CoV-2," and "C-reactive protein," among others, were searched to find relevant papers. Only studies that reported mean C-reactive protein levels and COVID-19 disease stage results were included. The review contained twenty papers. All investigations indicated that individuals with severe COVID-19 had considerably greater levels of C-reactive protein than patients with moderate illness. This review indicated that a specific biomarker may still be used to predict the risk of disease progression in asymptomatic and/or slightly too seriously unwell persons.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.